Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series

BACKGROUND: Pulmonary hypertension (PH) is a known complication of pulmonary sarcoidosis and is associated with higher morbidity and mortality. Currently, there are no approved PH-targeted therapies for sarcoidosis-associated pulmonary hypertension (SAPH). Macitentan is frequently used as treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathijssen, H., Huitema, M.P., Bakker, A.L.M., Mager, J.J., Snijder, R.J., Grutters, J.C., Post, M.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569544/
https://www.ncbi.nlm.nih.gov/pubmed/33093771
http://dx.doi.org/10.36141/svdld.v37i1.9292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569544/
https://www.ncbi.nlm.nih.gov/pubmed/33093771
http://dx.doi.org/10.36141/svdld.v37i1.9292

Ejemplares similares